Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Mecasermin
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Esteve Huayi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
Details : Under the licensing agfreement, Esteve will hold the rights of Increlex (mecasermin). It is being indicated for the treatment of growth failure in children with severe primary IGF-1 deficiency.
Product Name : Increlex
Product Type : Hormone
Upfront Cash : Undisclosed
April 01, 2025
Lead Product(s) : Mecasermin
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Esteve Huayi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Hydrocortisone
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Crossject
Deal Size : Undisclosed
Deal Type : Collaboration
CROSSJECT Updates on ZENEO Partnership with Eton for Adrenal Program
Details : ETON in-licensed commercialization rights to ZENEO® Hydrocortisone, a unique, and proprietary ready-to-use liquid formulation of hydrocortisone, for the US and Canadian markets.
Product Name : Zeneo
Product Type : Steroid
Upfront Cash : Undisclosed
March 25, 2025
Lead Product(s) : Hydrocortisone
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Crossject
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharma Reports Positive Pivotal Study Results for ET-600 Candidate
Details : ET-600 is a proprietary, patented oral solution of desmopressin, which is under development for the treatment of central diabetes insipidus.
Product Name : ET-600
Product Type : Hormone
Upfront Cash : Inapplicable
March 14, 2025
Lead Product(s) : Desmopressin Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zinc Acetate Dihydrate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
Details : Galzin (zinc acetate) is FDA-approved for the maintenance treatment of patients with Wilson disease who have been initially treated with a chelating agent.
Product Name : Galzin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 03, 2025
Lead Product(s) : Zinc Acetate Dihydrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals’ ET-400 NDA Accepted by FDA
Details : ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.
Product Name : ET-400
Product Type : Steroid
Upfront Cash : Inapplicable
July 15, 2024
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Submits New Drug Application to FDA for ET-400 (Hydrocortisone Oral Solution)
Details : ET-400 is Eton’s proprietary patented formulation of hydrocortisone oral solution. Company has submitted NDA for ET-400 use in endocrine system disorders.
Product Name : ET-400
Product Type : Steroid
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : Hydrocortisone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ethanol
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
Details : USFDA has accepted for review the company’s NDA response for dehydrated alcohol injection (a nerve blocking agent) for the proposed indication of methanol poisoning.
Product Name : DS-100
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 01, 2023
Lead Product(s) : Ethanol
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Betaine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels. The program will provide prescription fulfillment, insurance benefits investigation, educational suppo...
Product Name : Cystadane-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : Betaine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ethanol
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
Details : FDA issued a Complete Response Letter (CRL) in response to its New Drug Application (NDA) for dehydrated alcohol injection for the treatment of methanol poisoning.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Ethanol
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-Cysteine Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Details : U.S.FDA granted company,180 days of generic exclusivity as a result of being the first ANDA submitted for cysteine hydrochloride injection, a bioequivalent generic of Exela Pharma Sciences’ Elcys, against the reference product.
Product Name : Cysteine Hydrochloride - Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 04, 2022
Lead Product(s) : L-Cysteine Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable